X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ophthalmology (1679) 1679
humans (1598) 1598
bevacizumab (1528) 1528
avastin (1439) 1439
male (1016) 1016
female (1006) 1006
vascular endothelial growth factor a - antagonists & inhibitors (875) 875
aged (800) 800
middle aged (781) 781
antibodies, monoclonal, humanized (763) 763
endothelial growth-factor (726) 726
ranibizumab (693) 693
macular degeneration (691) 691
angiogenesis inhibitors - administration & dosage (665) 665
angiogenesis inhibitors - therapeutic use (628) 628
intravitreal injections (549) 549
treatment outcome (547) 547
vascular endothelial growth factor (488) 488
injection (485) 485
retrospective studies (448) 448
adult (438) 438
injections (436) 436
aged, 80 and over (430) 430
tomography, optical coherence (426) 426
antibodies, monoclonal - administration & dosage (423) 423
vitreous body (393) 393
fluorescein angiography (388) 388
bevacizumab avastin (377) 377
neovascularization (368) 368
visual acuity - physiology (366) 366
antibodies, monoclonal - therapeutic use (360) 360
follow-up studies (352) 352
choroidal neovascularization (346) 346
intravitreal bevacizumab avastin (344) 344
diabetic retinopathy (329) 329
photodynamic therapy (318) 318
intravitreal bevacizumab (314) 314
choroidal neovascularization - drug therapy (312) 312
therapy (299) 299
visual acuity (290) 290
eye diseases (287) 287
prospective studies (282) 282
macular degeneration - drug therapy (275) 275
angiogenesis (262) 262
animals (257) 257
vegf (257) 257
angiogenesis inhibitors (253) 253
angiogenesis inhibitors - adverse effects (247) 247
macular edema - drug therapy (239) 239
macular edema (233) 233
age-related macular degeneration (231) 231
antibodies, monoclonal, humanized - administration & dosage (227) 227
intravitreal injection (225) 225
safety (213) 213
verteporfin (211) 211
genetic structures (207) 207
care and treatment (206) 206
retinopathy (205) 205
medicine & public health (198) 198
antibodies, monoclonal, humanized - therapeutic use (192) 192
choroidal neovascularization - etiology (191) 191
secondary (187) 187
retina (186) 186
optical coherence tomography (181) 181
antibodies, monoclonal - adverse effects (180) 180
surgery (179) 179
diabetic retinopathy - drug therapy (176) 176
triamcinolone acetonide (175) 175
sense organs (172) 172
vitrectomy (172) 172
pharmacology & pharmacy (171) 171
edema (150) 150
triamcinolone (150) 150
visual acuity - drug effects (146) 146
research (138) 138
macular edema - etiology (135) 135
pharmacokinetics (134) 134
diabetes (133) 133
physiological aspects (133) 133
efficacy (132) 132
anti-vegf (131) 131
choroidal neovascularization - physiopathology (131) 131
combined modality therapy (130) 130
cancer (126) 126
diabetic macular edema (126) 126
expression (123) 123
abridged index medicus (119) 119
drug therapy (119) 119
macular degeneration - complications (118) 118
pegaptanib (118) 118
retina - pathology (116) 116
analysis (112) 112
vascular endothelial growth factor a - metabolism (109) 109
retinal vein occlusion (108) 108
photochemotherapy (107) 107
macular degeneration - physiopathology (104) 104
retinal vein occlusion - complications (100) 100
retinal vein occlusion - drug therapy (99) 99
retreatment (98) 98
lucentis (97) 97
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2242) 2242
Chinese (90) 90
German (90) 90
French (31) 31
Portuguese (23) 23
Spanish (15) 15
Korean (11) 11
Russian (8) 8
Japanese (7) 7
Czech (3) 3
Persian (2) 2
Hebrew (1) 1
Hungarian (1) 1
Polish (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2012, Volume 119, Issue 7, pp. 1399 - 1411
Purpose To compare the efficacy and safety of ranibizumab and bevacizumab intravitreal injections to treat neovascular age-related macular degeneration (nAMD).... 
Ophthalmology | DIABETIC-RETINOPATHY | OPHTHALMOLOGY | AVASTIN | DESIGN | INTRAVITREAL BEVACIZUMAB | Macular degeneration | Chronic diseases | Angiogenesis inhibitors | Universities and colleges
Journal Article
Colloids and surfaces, B, Biointerfaces, ISSN 0927-7765, 11/2017, Volume 159, pp. 241 - 250
Journal Article
by Wang, J and Qi, L and Liu, L and Wang, ZJ and Chen, G and Wang, Y and Liu, XN and Liu, Y and Liu, HJ and Tong, YX and Liu, C and Lei, CP and Wang, XH
FRONTIERS IN PHARMACOLOGY, ISSN 1663-9812, 08/2019, Volume 10, p. 905
Objective: This study compared the pharmacokinetics (PK), safety, and immunogenicity of the biosimilar TAB008 monoclonal antibody to bevacizumab (AvastiN (R))... 
BLIND | TAB008 monoclonal antibody injection | SAFETY | pharmacokinetics | PHARMACOLOGY & PHARMACY | Avastin (R) | CHINESE PATIENTS | immunogenicity | biosimilarity | Monoclonal antibodies | Dosage and administration | Avastin
Journal Article
Ophthalmology, ISSN 0161-6420, 2013, Volume 120, Issue 10, pp. 2035 - 2041
Journal Article
Ophthalmic Epidemiology, ISSN 1744-5086, 2009, Volume 14, Issue 4, pp. 179 - 183
Journal Article